Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Treasury Shares (2020 - 2025)

Historic Treasury Shares for Heron Therapeutics (HRTX) over the last 6 years, with Q3 2025 value amounting to $4.0 million.

  • Heron Therapeutics' Treasury Shares rose 15946.99% to $4.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.0 million, marking a year-over-year increase of 15946.99%. This contributed to the annual value of $2.0 million for FY2024, which is 4099.64% up from last year.
  • As of Q3 2025, Heron Therapeutics' Treasury Shares stood at $4.0 million, which was up 15946.99% from $4.1 million recorded in Q2 2025.
  • In the past 5 years, Heron Therapeutics' Treasury Shares registered a high of $1.8 billion during Q3 2023, and its lowest value of $570000.0 during Q1 2021.
  • Its 5-year average for Treasury Shares is $96.2 million, with a median of $2.5 million in 2022.
  • In the last 5 years, Heron Therapeutics' Treasury Shares soared by 6330152.64% in 2023 and then crashed by 9991.34% in 2024.
  • Heron Therapeutics' Treasury Shares (Quarter) stood at $2.8 million in 2021, then increased by 12.99% to $3.2 million in 2022, then crashed by 55.64% to $1.4 million in 2023, then surged by 41.0% to $2.0 million in 2024, then skyrocketed by 102.62% to $4.0 million in 2025.
  • Its Treasury Shares stands at $4.0 million for Q3 2025, versus $4.1 million for Q2 2025 and $3.9 million for Q1 2025.